Gemina Laboratories Ltd.
GLABF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.49 | 0.29 | 69.89 | -0.01 |
| FCF Yield | -2.75% | -8.04% | -10.92% | -15.26% |
| EV / EBITDA | -12.80 | -7.99 | -7.12 | -5.19 |
| Quality | ||||
| ROIC | 123.74% | 462.41% | -3,537.89% | -478.07% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.32 | 0.62 | 0.75 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 60.40% | 28.42% | -18.23% | -1,116.43% |
| Safety | ||||
| Net Debt / EBITDA | -0.34 | -0.09 | -0.03 | 0.24 |
| Interest Coverage | -23.84 | -264.05 | 0.00 | -8,783.63 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,206.22 | -6,515.02 | -6,743.89 | -2,714.11 |